| V cases | V controls | BV cases | BV controls | B cases | B controls | Case series | ||
---|---|---|---|---|---|---|---|---|---|
Number of patients | 105 | 82 | 106 | 86 | 98 | 90 | χ 2 | p | |
Age at hist. diag. | Median (years) | 55.4 | 52.0 | 52.5 | 50.3 | 55.9 | 48.8 | Â | Â |
Grade | 1 | 3 (3%) | 12 (15%) | 3 (3%) | 13 (15%) | 8 (8%) | 7 (8%) | Â | Â |
 | 2 | 27 (26%) | 32 (39%) | 44 (42%) | 47 (55%) | 44 (45%) | 42 (47%) |  |  |
 | 3 | 68 (65%) | 34 (41%) | 55 (52%) | 19 (22%) | 38 (39%) | 37 (41%) |  |  |
 | Unknown | 7 (7%) | 4 (5%) | 4 (4%) | 7 (8%) | 8 (8%) | 4 (4%) | 18.2 | 0.01 |
ER IHC status | Positive | 57 (54%) | 52 (63%) | 69 (65%) | 62 (72%) | 77 (79%) | 65 (72%) | Â | Â |
 | Negative | 48 (46%) | 30 (37%) | 37 (35%) | 24 (28%) | 21 (21%) | 25 (28%) | 13.3 | 0.001 |
PR status | Positive | 39 (37%) | 40 (49%) | 53 (50%) | 56 (65%) | 59 (60%) | 51 (57%) | Â | Â |
 | Negative | 66 (63%) | 42 (51%) | 53 (50%) | 30 (35%) | 39 (40%) | 39 (43%) | 10.9 | 0.004 |
HER2 status | Positive | 31 (30%) | 13 (16%) | 22 (21%) | 13 (15%) | 15 (15%) | 11 (12%) | Â | Â |
 | Negative | 44 (42%) | 38 (46%) | 51 (48%) | 41 (48%) | 45 (46%) | 42 (47%) |  |  |
 | Unknown | 30 (29%) | 31 (38%) | 33 (31%) | 32 (37%) | 38 (39%) | 37 (41%) | 7.0 | 0.1 |
Tumour size | <= 2Â cm | 41 (39%) | 39 (48%) | 39 (37%) | 44 (51%) | 38 (39%) | 47 (52%) | Â | Â |
 | >2 cm | 64 (61%) | 42 (51%) | 65 (61%) | 38 (44%) | 60 (61%) | 41 (46%) | 0.1 | 1.0 |
 | Unknown | -- -- | 1 (1%) | 2 (2%) | 4 (5%) | -- -- | 2 (2%) |  |  |
Lymph nodes positive | 0 | 15 (14%) | 33 (40%) | 21 (20%) | 32 (37%) | 24 (24%) | 39 (43%) | Â | Â |
 | 1–3 | 34 (32%) | 29 (35%) | 31 (29%) | 28 (33%) | 30 (31%) | 30 (33%) |  |  |
 | 4+ | 37 (35%) | 10 (12%) | 40 (38%) | 11 (13%) | 26 (27%) | 10 (11%) |  |  |
 | Unknown | 19 (18%) | 10 (12%) | 14 (13%) | 15 (17%) | 18 (18%) | 11 (12%) | 6.1 | 0.4 |
Invasive subtype | NOS/no special type | 96 (91%) | 70 (85%) | 85 (82%) | 73 (85%) | 82 (84%) | 81 (90%) | Â | Â |
 | Ductal - mucinous | -- -- | 2 (2%) | 1 (1%) | -- -- | 1 (1%) | 1 (1%) |  |  |
 | Ductal - tubular | -- -- | -- -- | 1 (1%) | 3 (3%) | 2 (2%) | 1 (1%) |  |  |
 | Ductal - other | 1 (1%) | 1 (1%) | 1 (1%) | -- -- | -- -- | 3 (3%) |  |  |
 | Lobular - classical | 5 (5%) | 5 (6%) | 7 (7%) | 9 (10%) | 12 (12%) | 2 (2%) |  |  |
 | Lobular - pleomorphic | 1 (1%) | 1 (1%) | 6 (6%) | -- -- | -- -- | 1 (1%) |  |  |
 | Lobular - other | -- -- | 2 (2%) | 2 (2%) | 1 (1%) | 1 (1%) | -- -- |  |  |
 | Other | 2 (2%) | 1 (1%) | 1 (1%) | -- -- | -- -- | 1 (1%) | 1.7 | 0.4 †|
Surgery type (any time) | Breast conserving | 30 (29%) | 34 (41%) | 35 (33%) | 43 (50%) | 31 (32%) | 39 (43%) | Â | Â |
 | Breast conserving + mastectomy | 17 (16%) | 11 (13%) | 19 (18%) | 7 (8%) | 15 (15%) | 13 (14%) |  |  |
 | Mastectomy | 47 (45%) | 33 (40%) | 41 (39%) | 30 (35%) | 43 (44%) | 35 (39%) |  |  |
 | Unknown | 11 (10%) | 4 (5%) | 11 (10%) | 6 (7%) | 9 (9%) | 3 (3%) | 1.2 | 1.0 |
Radiotherapy (adj/neo) | Yes | 79 (75%) | 52 (63%) | 84 (79%) | 55 (64%) | 82 (84%) | 59 (66%) | Â | Â |
 | No | 26 (25%) | 30 (37%) | 22 (21%) | 31 (36%) | 16 (16%) | 31 (34%) | 2.2 | 0.3 |
Hormone treatment (adj/neo) | Yes | 84 (80%) | 38 (46%) | 97 (92%) | 57 (66%) | 92 (94%) | 51 (57%) | Â | Â |
 | No | 21 (20%) | 44 (54%) | 9 (8%) | 29 (34%) | 6 (6%) | 39 (43%) | 11.0 | 0.004 |
Chemotherapy | Neo-adj only | -- -- | 2 (2%) | 2 (2%) | 1 (1%) | 5 (5%) | 3 (3%) | Â | Â |
 | Neo-adj and adj | 4 (4%) | -- -- | 4 (4%) | 1 (1%) | 1 (1%) | -- -- |  |  |
 | Adj only | 65 (62%) | 33 (40%) | 67 (63%) | 24 (28%) | 43 (44%) | 28 (31%) |  |  |
 | No | 36 (34%) | 47 (57%) | 33 (31%) | 60 (70%) | 49 (50%) | 59 (66%) | 8.7 | 0.01 ‡ |
Metastatic events in control series | No mets, 64 (78%) V = 8, BV = 8, B = 2 | No mets, 66 (77%) V = 10, BV = 5, B = 5 | No mets, 69 (77%) V = 4, BV = 10, B = 7 |  |